Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CC10004 Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Apremilast Pregnancy Exposure Registry

NCT02775500
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis
Interventions
apremilast
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Apremilast for Erythema Multiforme

NCT05875714
View directory record Official record
Conditions
Erythema Multiforme
Interventions
Apremilast
Drug
Lead sponsor
Robert Micheletti
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT03701763
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast (CC-10004), Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

NCT01285310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Apremilast 30 mg, Apremilast 20 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

NCT02425826
View directory record Official record
Conditions
Parapsoriasis
Interventions
Apremilast, Placebo, Placebo-Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

NCT04306965
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933
View directory record Official record
Conditions
Chronic Hand Dermatitis
Interventions
Apremilast 30mg
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

NCT03442088
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
CC-100004
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

NCT02307513
View directory record Official record
Conditions
Behçet's Syndrome
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

NCT03441789
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar, Vehicle, Otezla
Drug
Lead sponsor
L.H. Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Apremilast in Palmo-Plantar Psoriasis

NCT02400749
View directory record Official record
Conditions
Palmo-plantar Psoriasis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Innovaderm Research Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Not listed Phase 4 Interventional

The Maintenance Effect of Enstilar Foam in Combination With Otezla

NCT04555707
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast 30mg, calcipotriene and betamethasone dipropionate
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625
View directory record Official record
Conditions
Lichen Planus
Interventions
Apremilast (CC-10004)
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Apremilast for Alcohol Use Disorder Treatment in Women and Men

NCT06324435
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Apremilast
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder

NCT07029529
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Apremilast 60mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

NCT02641353
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Tablet, Apremilast Oral Suspension
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults

NCT01634178
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

NCT02236988
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Immediate Release, Apremilast Modified Release 1, Apremilast Modified Release 2, Apremilast Modified Release 3, Apremilast Modified Release 4, Apremilast Modified Release 5, Apremilast Modified Release 6, Apremilast Modified Release 8, Apremilast Modified Release 9, Apremilast Modified Release 11, Apremilast Modified Release 12, Apremilast Modified Release 13, Apremilast Modified Release 14
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 2, 2026, 4:40 PM EDT